Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland
| Autor: | Christian Garzoni, Arnaud Riat, Dionysios Neofytos, Nina Khanna, Jizhou Li, Katia Boggian, A Kritikos, Frédéric Lamoth, Dominique Sanglard, Daniel Bachmann, C Zehnder, Daniel Goldenberger, Alix T. Coste |
|---|---|
| Přispěvatelé: | Fungal Infection Network of Switzerland (FUNGINOS), Lamoth, F., Khanna, N., Boggian, K., Sanglard, D. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine Microbiology (medical) Antifungal Agents Echinocandin 030106 microbiology Candida glabrata Microbiology Echinocandins 03 medical and health sciences Drug Resistance Fungal Candida albicans polycyclic compounds Humans Medicine Aged Aged 80 and over ddc:616 biology business.industry Brief Report Candidemia General Medicine Middle Aged biology.organism_classification bacterial infections and mycoses 030104 developmental biology Infectious Diseases Candida spp Female business Switzerland medicine.drug |
| Zdroj: | Infection, Vol. 48, No 5 (2020) pp. 761-766 Infection, vol. 48, no. 5, pp. 761-766 Infection |
| ISSN: | 0300-8126 |
| Popis: | Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15–77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink